latest update:
[TrialBase DB]

trial summary · NCT07069699

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Burkitt Lymphoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07069699phase PHASE1/PHASE2enrollment 50start 2027-01-11

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma.

Source record: https://clinicaltrials.gov/study/NCT07069699

Facts

registry idNCT07069699
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionBurkitt Lymphoma
sponsorNational Cancer Institute (NCI)
sponsor classNIH
enrollment50
start date2027-01-11
primary completion2030-01-31
completion2030-01-31
results postednot reported

Conditions

  • Burkitt Lymphoma
  • Double-Expressor Lymphoma
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

Interventions

  • Biopsy Procedure
  • Biospecimen Collection
  • Computed Tomography
  • Lumbar Puncture
  • Pidnarulex
  • Positron Emission Tomography

Countries

  • United States

Intervention types: DRUG, PROCEDURE

Work with this record